newsfilter
← Latest News
GlobeNewswire·

Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks

If approved, deucrictibant will be the first oral bradykinin B2 receptor antagonist to treat HAE attacksNDA includes positive data from successful clinical program demonstrating rapid relief and sustained response to